JP6480467B2 - 疎水性薬物送達のための新規なポリマーベースのヒドロトロープ - Google Patents

疎水性薬物送達のための新規なポリマーベースのヒドロトロープ Download PDF

Info

Publication number
JP6480467B2
JP6480467B2 JP2016561865A JP2016561865A JP6480467B2 JP 6480467 B2 JP6480467 B2 JP 6480467B2 JP 2016561865 A JP2016561865 A JP 2016561865A JP 2016561865 A JP2016561865 A JP 2016561865A JP 6480467 B2 JP6480467 B2 JP 6480467B2
Authority
JP
Japan
Prior art keywords
polymer
polymer conjugate
hydrophobic
group
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016561865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516883A5 (enExample
JP2017516883A (ja
Inventor
イン,ウェンビン
イン ツァン,コク
イン ツァン,コク
バイ,ハオ
イン,ハイチン
リュー,ジーフア
ワン,リー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of JP2017516883A publication Critical patent/JP2017516883A/ja
Publication of JP2017516883A5 publication Critical patent/JP2017516883A5/ja
Application granted granted Critical
Publication of JP6480467B2 publication Critical patent/JP6480467B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10Alpha-amino-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48Polymers modified by chemical after-treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nanotechnology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polyamides (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
JP2016561865A 2014-04-07 2014-09-01 疎水性薬物送達のための新規なポリマーベースのヒドロトロープ Expired - Fee Related JP6480467B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461976354P 2014-04-07 2014-04-07
US61/976,354 2014-04-07
PCT/JP2014/004480 WO2015155810A1 (en) 2014-04-07 2014-09-01 Novel polymer-based hydrotropes for hydrophobic drug delivery

Publications (3)

Publication Number Publication Date
JP2017516883A JP2017516883A (ja) 2017-06-22
JP2017516883A5 JP2017516883A5 (enExample) 2017-10-19
JP6480467B2 true JP6480467B2 (ja) 2019-03-13

Family

ID=51535486

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016561865A Expired - Fee Related JP6480467B2 (ja) 2014-04-07 2014-09-01 疎水性薬物送達のための新規なポリマーベースのヒドロトロープ

Country Status (10)

Country Link
US (1) US10080737B2 (enExample)
EP (1) EP3129425B1 (enExample)
JP (1) JP6480467B2 (enExample)
KR (1) KR102256453B1 (enExample)
CN (1) CN106133024B (enExample)
AU (1) AU2014390729B2 (enExample)
CA (1) CA2943733C (enExample)
RU (1) RU2676680C2 (enExample)
TW (1) TWI694838B (enExample)
WO (1) WO2015155810A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105801847A (zh) * 2016-03-16 2016-07-27 华东师范大学 一种用于抗肿瘤药物递送的助溶高分子载体及制备方法
CN112402617B (zh) * 2020-11-20 2023-06-09 汕头大学 血影紫杉醇及其制备方法与应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5811119A (en) 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US20040028682A1 (en) 1989-09-29 2004-02-12 Border Wayne A. Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix
DK0494264T3 (da) 1989-09-29 1998-01-26 Jolla Cancer Res Found Inhibering af transformede vækstfaktor til hindring af akkumulation af ekstracellulær matrix
US5234604A (en) 1991-02-26 1993-08-10 Betz Laboratories, Inc. Water soluble block copolymers and methods of use therof
AU670777B2 (en) 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
JPH08268906A (ja) 1995-03-31 1996-10-15 Sumitomo Pharmaceut Co Ltd 肺線維症予防剤
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US5851538A (en) 1995-12-29 1998-12-22 Advanced Polymer Systems, Inc. Retinoid formulations in porous microspheres for reduced irritation and enhanced stability
US6183774B1 (en) 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
CA2300938A1 (en) 1997-08-20 1999-02-25 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
JPH11269076A (ja) 1998-01-22 1999-10-05 Seikagaku Kogyo Co Ltd 抗線維化剤
DE60045890D1 (de) 1999-04-27 2011-06-09 Mitsubishi Tanabe Pharma Corp Arzneimittel zur präventiven oder therapeutische Behandlung von Lebererkrankungen
US20020041898A1 (en) 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
CA2402613A1 (en) 2000-03-29 2001-10-04 Igor Gonda Cationic liposomes
JP2002047211A (ja) 2000-08-04 2002-02-12 Japan Science & Technology Corp 脂溶性物質と生理活性高分子物質結合体および細胞核内への導入方法
EP1392366A4 (en) 2001-04-13 2005-01-19 Population Council Inc CORE RECEPTOR-MEDIATED INTRODUCTION OF A PNA PROTEIN IN CELL CHERRIES
JP4547696B2 (ja) 2001-06-07 2010-09-22 第一三共株式会社 肝硬変予防・治療剤
JP2002371006A (ja) 2001-06-11 2002-12-26 Mochida Pharmaceut Co Ltd 肺線維症予防および/または進行防止剤
JP2003119138A (ja) 2001-10-09 2003-04-23 Tohoku Techno Arch Co Ltd 間質性肺炎および/または肺線維症の予防治療剤
ATE359829T1 (de) 2001-10-30 2007-05-15 Nektar Therapeutics Al Corp Wasserlösliche polymerkonjugate von retinoesäure
JP3803318B2 (ja) 2001-11-21 2006-08-02 株式会社RNAi 遺伝子発現阻害方法
ES2401326T3 (es) 2001-11-21 2013-04-18 Astellas Pharma Inc. Procedimiento para inhibir la expresión génica
AU2002343094A1 (en) 2001-11-26 2003-06-10 Arachnova Therapeutics Ltd. Use of ppar activators for the treatment of pulmonary fibrosis
DE60326833D1 (de) 2002-05-15 2009-05-07 Endocyte Inc Vitamin-mitomycin-konjugate
MXPA04012664A (es) 2002-06-19 2005-08-15 Raven Biotechnologies Inc Objetivo de superficie celular raag10 novedoso y una familia de anticuerpos que reconocen ese objetivo.
FR2843117B1 (fr) * 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
WO2004019758A2 (en) 2002-08-27 2004-03-11 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
US20050191302A1 (en) 2002-08-29 2005-09-01 University Of Southampton Treatment for liver disease
TWI367096B (en) 2003-01-27 2012-07-01 Endocyte Inc Vitamin-receptor binding drug delivery conjugates and pharmaceutical compositions
CA2488224A1 (en) 2003-04-03 2004-10-21 Alnylam Pharmaceuticals, Inc. Irna conjugates
FR2855521B1 (fr) * 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
WO2005084702A1 (ja) 2004-03-02 2005-09-15 Hokkaido Technology Licensing Office Co., Ltd. 臓器線維症予防・治療剤
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
PL2727583T3 (pl) 2004-12-22 2022-02-07 Nitto Denko Corporation Nośnik leku i zestaw z nośnikiem leku do hamowania włóknienia
US20130171240A1 (en) 2004-12-22 2013-07-04 Nitto Denko Corporation Drug carrier and drug carrier kit for inhibiting fibrosis
JP2009221164A (ja) 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
ATE432955T1 (de) * 2005-12-05 2009-06-15 Nitto Denko Corp Polyglutamat-aminosäure-konjugate und verfahren
GB0524987D0 (en) 2005-12-08 2006-01-18 Ge Healthcare Ltd Novel imaging agents for fibrosis
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
JP5342834B2 (ja) 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
US20130210744A1 (en) 2007-03-30 2013-08-15 Nitto Denko Corporation Targeting agent for cancer cell or cancer-associated fibroblast
US8197828B2 (en) * 2007-05-09 2012-06-12 Nitto Denko Corporation Compositions that include a hydrophobic compound and a polyamino acid conjugate
CA2698812A1 (en) 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
WO2010014117A1 (en) * 2008-07-30 2010-02-04 Nitto Denko Corporation Drug carriers
EP2337587A4 (en) 2008-09-12 2015-02-18 Nitto Denko Corp IMAGING AGENTS FOR FIBROTIC DISEASES
PT2509991E (pt) 2009-12-09 2016-01-12 Nitto Denko Corp Modulação da expressão de hsp47
CN102933233A (zh) 2010-06-17 2013-02-13 日东电工株式会社 肾纤维化处理剂
US20160015656A2 (en) 2010-08-05 2016-01-21 Nitto Denko Corporation Composition for regenerating normal tissue from fibrotic tissue
JP5950428B2 (ja) 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
KR101786905B1 (ko) 2011-06-21 2017-10-19 닛토덴코 가부시키가이샤 아포토시스 유도제
TWI627965B (zh) 2011-11-18 2018-07-01 日東電工股份有限公司 腸道纖維化處置劑
ES2677478T3 (es) * 2012-04-12 2018-08-02 Nitto Denko Corporation Conjugados de copolímero

Also Published As

Publication number Publication date
AU2014390729B2 (en) 2018-11-29
RU2016143395A3 (enExample) 2018-05-07
KR20170016822A (ko) 2017-02-14
CN106133024A (zh) 2016-11-16
CA2943733A1 (en) 2015-10-15
KR102256453B1 (ko) 2021-05-25
RU2016143395A (ru) 2018-05-07
JP2017516883A (ja) 2017-06-22
EP3129425A1 (en) 2017-02-15
RU2676680C2 (ru) 2019-01-10
US20150283253A1 (en) 2015-10-08
US10080737B2 (en) 2018-09-25
AU2014390729A1 (en) 2016-11-17
WO2015155810A1 (en) 2015-10-15
TW201540312A (zh) 2015-11-01
TWI694838B (zh) 2020-06-01
CN106133024B (zh) 2019-07-05
EP3129425B1 (en) 2019-04-10
CA2943733C (en) 2022-03-01

Similar Documents

Publication Publication Date Title
JP6740391B2 (ja) 安定なミセルのためのブロックコポリマー
CN102037058B (zh) 多西紫杉醇高分子衍生物、及其制造方法及其用途
US20100278927A1 (en) Polymeric micelles for polynucleotide encapsulation
JP2007500229A5 (enExample)
KR20100022000A (ko) 소수성 제제를 캡슐화하기 위해 사용되는 혼합 입체화학을 가지는 혼성 블록 공중합체 미셀
WO2008134761A2 (en) Modification of biological targeting groups for the treatment of cancer
KR102465349B1 (ko) 신규 이온화 지질 및 이를 포함하는 지질 나노입자
KR20180097707A (ko) 생분해성 양친매성 폴리머, 그것에 의해 제조되는 폴리머 베시클, 및 폐암표적 치료제의 제조에 있어서의 사용
CN103800915B (zh) 一种靶向整合素受体的联合载药胶束及其制备方法
WO2016167333A1 (ja) ポリ(l-アルギニン)セグメント含有ブロック共重合体とポリアニオン性ポリマーのポリイオンコンプレックス
JP7506659B2 (ja) 癌を処置する方法に用いられるコンジュゲート
CN111793147A (zh) 改性壳聚糖、双响应纳米载体药及其制备方法和应用
JP6480467B2 (ja) 疎水性薬物送達のための新規なポリマーベースのヒドロトロープ
US20130266661A1 (en) Amphiphilic cyclic phosphazene trimer, pharmaceutical formulation of hydrophobic drugs by micelle-encapsulation using the amphiphilic cyclic phosphazene trimer, and preparation methods thereof
JP2022546748A (ja) 再生可能資源に由来するポリマーおよび組成物
KR20240082390A (ko) 생분해성 에스터 결합을 포함하는 이온화 가능한 지질 및 이를 포함하는 지질나노입자
KR20250111222A (ko) 신규 이온화 가능한 지질 및 이를 포함하는 지질나노입자
CN116813515B (zh) 一种姜黄素衍生物前药、其制备方法和应用
CN110214145B (zh) CP-iRGD多肽、iDPP纳米粒、载药复合物及其制备方法和应用
US20240173255A1 (en) Polymeric Micelle Coated with Chain-Like Poorly Soluble Drug, Preparation Method and Application
CN109602694B (zh) 喜树碱前药凝胶及其制备方法和用途
KR102758330B1 (ko) 황화물을 포함하는 이온화 가능한 지질 및 이를 포함하는 지질나노입자
WO2025194120A1 (en) Zwitterionic polymer functionalized lipid nanoparticles for delivery of nucleic acids
CN119490447A (zh) 药物递送材料及其应用

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20161228

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20170627

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170907

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190207

R150 Certificate of patent or registration of utility model

Ref document number: 6480467

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees